E Fund Management Co., Ltd. Editas Medicine, Inc. Transaction History

E Fund Management Co., Ltd.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$4.67 - $7.28 $116,894 - $182,225	-25,031 Reduced 65.73%	13,051 $60,000
Q1 2024 May 13, 2024	BUY	$7.03 - $11.07 $133,204 - $209,754	18,948 Added 99.03%	38,082 $282,000
Q4 2023 Feb 06, 2024	SELL	$6.25 - $11.11 $39,506 - $70,226	-6,321 Reduced 24.83%	19,134 $193,000
Q3 2023 Nov 13, 2023	SELL	$6.92 - $9.31 $37,838 - $50,907	-5,468 Reduced 17.68%	25,455 $199,000
Q2 2023 Aug 11, 2023	SELL	$6.36 - $11.47 $50,447 - $90,980	-7,932 Reduced 20.41%	30,923 $254,000
Q1 2023 May 11, 2023	SELL	$7.03 - $11.53 $10,720 - $17,583	-1,525 Reduced 3.78%	38,855 $282,000
Q4 2022 Feb 14, 2023	BUY	$8.32 - $13.21 $85,596 - $135,904	10,288 Added 34.19%	40,380 $358,000
Q3 2022 Nov 14, 2022	SELL	$12.16 - $19.42 $112,467 - $179,615	-9,249 Reduced 23.51%	30,092 $368,000
Q2 2022 Aug 15, 2022	BUY	$9.99 - $21.35 $215,074 - $459,644	21,529 Added 120.87%	39,341 $465,000
Q1 2022 May 12, 2022	BUY	$14.08 - $27.63 $208,609 - $409,366	14,816 Added 494.53%	17,812 $339,000
Q1 2021 May 12, 2021	BUY	$39.71 - $90.58 $118,971 - $271,377	2,996 New	2,996 $125,000

250

57.1M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $83.9M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on E Fund Management Co., Ltd. with notifications on news.